Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 6 Protein (FAS), Active

Name: Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 6 Protein (FAS), Active
Brand: Beta LifeScience
SKU: BLC-06042P
Availability: InStock

Collections: All products, Buy cytokines, chemokines, and growth factors for research online, High-quality cytokines for advanced research, High-quality recombinant proteins, Tumor necrosis factors and receptors (tnfs)

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 6 Protein (FAS), Active is produced by our E.coli expression system. This is a protein fragment.
Purity	Greater than 95% as determined by SDS-PAGE and HPLC.
Endotoxin	Less than 1.0 EU/μg as determined by LAL method.
Activity	Fully biologically active when compared to standard. The ED50 as determined by its ability to inhibit the cytotoxicity of Jurkat cells is between 10-15 ug/ml in the presence of 2 ng/ml of rHuFas Ligand.
Uniprotkb	P25445
Target Symbol	FAS
Synonyms	FAS; APT1; FAS1; TNFRSF6; Tumor necrosis factor receptor superfamily member 6; Apo-1 antigen; Apoptosis-mediating surface antigen FAS; FASLG receptor; CD antigen CD95
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	Tag-Free
Complete Sequence	RLSSKSVNAQ VTDINSKGLE LRKTVTTVET QNLEGLHHDG QFCHKPCPPG ERKARDCTVN GDEPDCVPCQ EGKEYTDKAH FSSKCRRCRL CDEGHGLEVE INCTRTQNTK CRCKPNFFCN STVCEHCDPC TKCEHGIIKE CTLTSNTKCK EEGSRSN
Expression Range	17-173aa
Protein Length	Partial
Mol. Weight	17.6 kDa
Research Area	Cancer
Form	Lyophilized powder
Buffer	Lyophilized from a 0.2 µm filtered PBS, pH 7.4
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro).
Subcellular Location	[Isoform 1]: Cell membrane; Single-pass type I membrane protein. Membrane raft.; [Isoform 2]: Secreted.; [Isoform 3]: Secreted.; [Isoform 4]: Secreted.; [Isoform 5]: Secreted.; [Isoform 6]: Secreted.
Database References	HGNC: 11920 OMIM: 134637 KEGG: hsa:355 STRING: 9606.ENSP00000347979 UniGene: PMID: 30278467 CD95-mediated apoptosis induces Pim-1 down-regulation in Burkitt's lymphoma (BL) B-cells, but Pim-1 down-regulation cannot fully eradicate BL and leukaemia. PMID: 27641442 Fas single-nucleotide polymorphisms rs2234767 and rs1800682 are involved in the pathogenesis of Idiopathic Aplastic Anemia PMID: 29611722 The mRNA expression of FAS was lower in patients with TP53 mutation than TP53 wild-type. Our findings suggest that TP53 mutation is a potential negative predictor of metastatic melanoma treated with CTLA-4 blockade. PMID: 29793878 Complete local landscape for a defined molecular function-the alternative splicing of an exon (FAS/CD95 exon 6). The extensive epistasis in the landscape predicts that exonic regulatory sequences may diverge between species even when exon inclusion levels are functionally important and conserved by selection. PMID: 27161764 Paper analyses results of serum cytokines and lymphocyte apoptosis study in nodular goiter against the background of autoimmune thyroiditis and thyroid adenoma based on the cell preparedness to apoptosis, the number of apoptotic lymphocytes and the content of proapoptotic tumor necrosis factor-alpha, interleukins in serum, considering the polymorphism of BCL-2, CTLA-4 and APO-1 genes. PMID: 29250672 These results demonstrated that overexpression of ING4 can induce the apoptosis of melanoma cells and CD3+ T cells through signaling pathways such as the Fas/FasL pathway, and that ING4 gene therapy for melanoma treatment is a novel approach. PMID: 29207034 Tag7 activates lymphocytes capable of Fasl-Fas-dependent contact killing of virus-infected cells. PMID: 29083508 These results indicated that cMyc and Fas regulated the sensitivity of A549 cells to irradiation by regulating caspase8-mediated Bid activation and the subsequent association with the mitochondrial pathway of apoptosis. PMID: 28849062 this study characterized in juvenile systemic lupus erythematosus a distinct profile from adult SLE that comprises increased sFas, sTRAIL, and reduced sFasL, notably in patients with active disease and with nephritis. PMID: 28378099 results from the current study showed that the association of FAS-670A/G SNP with idiopathic azoospermia was not found in a population of men with idiopathic infertility. PMID: 28942044 The Btk-dependent PIP5K1gamma lipid kinase activation by Fas counteracts FasL-induced cell death. PMID: 28879546 Study identify genes highly expressed in Kras knockout lung cancer cells, including the Fas receptor gene. Antibodies that activate Fas receptor selectively induced apoptosis in Kras-independent lung cancer cells suggesting that FAS is involved in KRAS-related drug resistance. PMID: 28320962 The authors observed differential expression of CD95(Fas) in CD27(+) B-cells from cirrhotic patients that was inversely correlated with peripheral CD27(+) B-cell frequency. They conclude that peripheral CD27(+) memory B-cells in cirrhosis exhibit increased sensitivity to Fas-induced apoptosis in an activation-dependent manner to which endotoxin contributes, associated with reduced frequency of circulating memory B-cells. PMID: 27857173 the analysis of mRNA level showed that disease progression is associated with significantly increased expression of FasR and/or FasL. In conclusion, our observation seems to confirm that spherical model of cancer lines is more reliable for some sophisticated analysis because of their greater resemblance to the CSCs from human CRC samples in comparison to commonly used adherent cells PMID: 28766682 study indicates FAS-FASL promoter SNPs may promote the production of cross-reactive anti-ganglioside antibodies in GBS PMID: 29432441 In primary hyperparathyroidism, hyperplasias demonstrated the highest expression of TRAIL and Fas, whereas in adenomas it was increased compared to normal tissue, but lower than in hyperplasias. PMID: 27763797 Data suggest that Fas and TNFR1 are involved in glaucoma mechanisms in cornea; pro-apoptotic effect of anti-glaucoma medication clonidine on corneal epithelial cells triggers Fas/TNFR1-mediated, mitochondria-dependent signaling pathway. (Fas = Fas cell surface death receptor ; TNFR1 = TNF receptor superfamily member 1A) PMID: 28115640 These data suggested that YY1 may be important for apoptosis induction via the regulation of Fas during sepsis. Therefore, Fas may be a potential therapeutic target to prevent MOD through regulation of YY1 expression. Furthermore, YY1 and Fas expression in PBMCs may be used to as prognostic markers. PMID: 28447715 Fas activation rapidly changes the interconversion of PC and PI, which then drives enhanced endocytosis, thus likely propagating death signaling from the cell surface to mitochondria and other organelles PMID: 28299505 using pifithrin alpha we observed a decrease in apoptosis induced by MG132, and by APO-1 plus MG132, suggesting that restoration of APO-1 sensitivity occurs in part through an increase in both the levels and the activity of p53. The use of small molecules to inhibit the proteasome pathway might permit the activation of cell death, providing new opportunities for CC treatment. PMID: 27766434 Fas - 670A/G genotypes or alleles were not significantly different between controls and transplant recipients and among transplant recipients with and without acute rejection following pediatric renal transplantation PMID: 27109035 data suggest miR-374a is a negative regulator of Fas death receptor which is able to enhance the cell survival and protect retinal pigment epithelial cells against oxidative conditions. PMID: 28543858 CD3(+) CD8(+) NKG2D(+) T Lymphocytes Induce Apoptosis and Necroptosis in HLA-Negative Cells via FasL-Fas Interaction PMID: 28294381 High-grade gliomas (HGG) showed significantly lower FAS but higher FAS ligand (FAS-L) expression than high-grade gliomas (HGG). PMID: 29187439 Peripheral CD95 expression higher than 30% could be used among the exclusion criteria in a multicomponent score for mycosis fungoides diagnosis. PMID: 28206666 anti-apoptotic molecules BclxL and Bcl-2 and the pro-apoptotic factors BAD and BID cooperate to promote migration of triple-negative breast cancer cells stimulated with cl-CD95L. PMID: 27367565 Knockout (KO) or knockdown of caspase-8, CD95 or FADD prevents activation of Plk3 upon CD95 stimulation, suggesting a requirement of a functional death-inducing signaling complex for Plk3 activation. PMID: 27325299 STAT1 is a key regulator of the cancer stem cell-inducing activity of CD95. PMID: 28273453 Two unrelated patients with severe recessive autoimmune lymphoproliferative syndrome had rare splicing defects in exon 6 of FAS. PMID: 28668589 CD95-induced senescence was caused by chronic DNA damage. PMID: 28300842 CD95 maintains stem cell-like and non-classical epithelial-mesenchymal transition programs in primary human glioblastoma cells. PMID: 27124583 Data (including data from studies using tissues from transgenic mice) suggest that IL1B plays dual roles by (1) mediating islet amyloid-induced FAS up-regulation and apoptosis in pancreatic beta-cells and (2) down-regulating IAPP precursor processing thereby potentiating islet amyloid formation. (IL1B = interleukin-1beta; FAS = FAS cell surface death receptor; IAPP = islet amyloid polypeptide) PMID: 28058779 MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers. PMID: 28649004 no association between the FAS polymorphism (rs1800682) and the susceptibility to persistent precancerous lesions and cervical cancer. PMID: 27899077 These findings suggest that rs1800682, rs2234767, and rs763110 genotypes are not associated with the presence of HTLV-1-associated myelopathy/tropical spastic paraparesis, but that the FAS-670 AA genotype can promote higher proviral load values in HTLV-1-associated myelopathy/tropical spastic paraparesis patients. PMID: 27603042 findings showed the variant allele and genotype of the FAS c.-671A>G polymorphism were significantly associated with increased risk of cervical cancer in Malaysian population, particularly those of Malay ethnicity; however, results of meta-analysis showed a lack of association between the polymorphism and cervical cancer risk PMID: 28279307 Fas cell surface death receptor (FAS) was identified as an independent prognostic marker for recurrence free survival in breast cancer, with large variation in expression by receptor subtypes. PMID: 28121628 data also demonstrated that the CD154-triggered inhibition of the Fas-mediated cell death response was dependent on a suppression of caspase-8 cleavage, but independent of de novo protein synthesis or alterations in Fas expression on cell surface. PMID: 27391025 We have identified two single nucleotide polymorphisms in two immune-related genes ( MBL" and CD95) that have an association with severe and potentially life-threatening infection following doxorubicin and cyclophosphamide therapy for breast cancer PMID: 27940354 With rs7901656 on the FAS gene as a paradigm, we show how allele specific transcription factor complex assembly and disruption by a causal variant contributes to disease and phenotypic diversity PMID: 27616356 Increased TIM3+CD8+T cells with lower perforin and granzyme B expression and higher CD95 expression in MDS patients were observed. PMID: 27846431 FAS c.-671AG genotype is not to be a risk factor in familial mediterranean fever. PMID: 28442396 functional inhibition of miR-29c caused resistance to Fas-mediated apoptosis in lung fibroblasts. PMID: 27765762 Most of the plasma cells of a paient with a heterozygous germline FAS mutation were Fas-deficient suggesting that Fas signaling plays a role also in the selection of germinal center B cells into the pool of long-lived plasma cells, similar to switched memory B cells. PMID: 26907631 a substantial subgroup of the ITP patients displayed a defective Fas function; most of them displayed decreased Fas expression in T cells activated in vitro. PMID: 27391055 Fas gene polymorphism is associated with Hashimoto's thyroiditis. PMID: 27572459 There is a positive correlation of the serum level of sFasL( Fas/FasL axis ) with uptake index of parotid gland in our expectation. In addition, liver injury involvement in SS patients showed decreased level of sFasL. Furthermore, we here also observed that the protective cytokine IL-10 expression was positively correlated with sFasL expression PMID: 28326325 The Fas-1377G > A polymorphism is associated with a higher risk of pre-eclampsia. PMID: 27277758 Fas rs2234767 G/A SNPs might be associated with an increased risk of rheumatoid arthritis. PMID: 26905515

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 6 Protein (FAS), Active

Recombinant Human Tumor Necrosis Factor Receptor Superfamily Member 6 Protein (FAS), Active

Product Overview

Target Details

FAQs